摘要:
A process for preparing dermatan sulphate (DS) of pharmaceutical purity from animal organs rich in micropolysaccharides (MPS), by: a) stabilizing the fresh organs by freezing them either as such or in the form of powder, b) micronizing the material containing the MPS with an aqueous CaCl.sub.2 solution, c) digesting the homogenate comprising the raw material and the CaCl.sub.2 with proteolytic enzyme at alkaline pH and at low temperature, d) acidifying, heating and filtering the lysate, e) treating the filtrate with quaternary ammonium salts able to undergo complexing with and thus precipitate either the DS alone or all the MPS selectively, f) recovering and purifying the DS either directly from the ammonium salt complex containing it or from the complex obtained from the mixture of ammonium salt complexes of all the MPS by fractional solubilization with acetone.
摘要:
A process for preparing dermatan sulphate (DS) of pharmaceutical purity from animal organs rich in mucopolysaccharides (MPS), by: (a) stabilizing the fresh organs by freezing them either as such or in the form of powder, (b) micronizing the material containing the MPS with an aqueous CaCl.sub.2 solution, (c) digesting the homogenate comprising the raw material and the CaCl.sub.2 with proteolytic enzymes at alkaline pH and at low temperature, (d) acidifying, heating and filtering the lysate, (e) treating the filtrate with quaternary ammonium salts able to undergo complexing with and thus precipitate either the DS along or all the MPS selectively, (f) recovering and purifying the DA either directly from the ammonium salt complex containing it or from the complex obtained from the mixture of ammonium salt complexes of all the MPS by fractional solubilization with acetone.
摘要:
A process for producing natural heparan sulphate and dermatan sulphate for mixtures of proteoglycans from the aorta, myocardium and particularly vascularized organs, based on a series of precipitation and purification steps which enable the protein part of the proteoglycan to be eliminated and the two products to be obtained in substantially pure form, without any chemical or enzymatic degradation.When administered orally or parenterally, the heparan sulphate obtained exerts activation effects on antithrombin III and on the fibrinolytic process.The dermatan sulphate obtained exerts an inhibiting effect on Factor Xa and also possesses the property of activating the fibrinolytic effect of heparan sulphate.
摘要:
A process for the controlled preparation of low molecular weight glucosaminoglycans by treating conventional high molecular weight glucosaminoglycans in the solid state or in solution form with a rectilinear gamma ray beam at doses within the range of 2.5 to 20 Mrad supplied by successive irradiation stages with cooling intervals between one irradiation stage and the next in the dynamic phase.The mixture obtained is subjected to fractionation, purification, neutralization and lyophilization. The glucosaminoglycans obtained have a molecular weight of between 1000 and 35,000 daltons and are used for the preparation of pharmaceutical compositions possessing antithrombotic, fibinolytic, antiatherogenic and heparin cofactor II activation activity.
摘要:
The present invention relates to cosmetological and dermatological compositions comprising heparan sulfate. The invention further discloses a process for the purification of heparan sulfate for dermatological and cosmetological applications, which process comprises the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the resin by using conditions which result in selective desorption of hepar an sulfate. The cosmetological and dermatological compositions according to the invention show, inter alia, anti-age, lenitive, and whitening effect.
摘要:
The present invention is directed to a multistep process for the physical depolymerization of heparin wherein heparin is subjected to at least two γ-ray irradiations and wherein between two irradiation steps the depolymerised heparin is subjected to a separation step and only a fraction of the depolymerised heparin obtained from the first irradiation is subjected to the second irradiation step. It is also directed to heparin-derived oligosaccharide fractions obtainable by the process of the invention.
摘要:
The invention relates to a process for the depolymerization of glycosaminoglycanes characterized by the use of electron beam radiation, optionally in the presence of an organic compound selected from the group consisting of ethers, alcohols, aldehydes, amides and formic acid. The invention also relates to the intermediate depolymerized heparin obtained by the process. The intermediate depolymerized heparin can be dissolved in a buffer solution and fractionated by gel permeation for obtaining the desired molecular weight.
摘要:
The present invention relates to the use of glycosaminoglycans having an average/molecular weight of 2,400 D for the preparation of pharmaceutical compositions suitable for the treatment of senile dementia, in particular for the treatment of Alzheimer's disease or SDAT (Senile Dementia Alzheimer's Type) and of the cerebral neurological lesions from ictus and from traumas.
摘要:
Protease inhibitor is extracted from fresh or frozen organs of slaughtered animals by an enzymolysis operation which excludes any possibility of interference by azymic autolysis, the enzymolysis being stopped after a time not exceeding 4 hours, whereafter a lysate aqueous solution is obtained by filtration and a quaternary ammonium base is added to the lysate solution to precipitate insolubles, the filtrate being the fraction which contains the expected protease inhibitor.
摘要:
The invention relates to a process for the depolymerization of glycosaminoglycanes characterized by the use of UVC radiation. The invention also relates to the intermediate depolymerized heparin obtained by the process. The intermediate depolymerized heparin can be dissolved in a buffer solution and fractionated by gel permeation for obtaining the desired molecular weight.